Quoin PharmaceuticalsQNRX
About: Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Employees: 4
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
25% more funds holding
Funds holding: 8 [Q1] → 10 (+2) [Q2]
0.27% more ownership
Funds ownership: 5.26% [Q1] → 5.53% (+0.27%) [Q2]
30% less capital invested
Capital invested by funds: $183K [Q1] → $128K (-$55.5K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for QNRX.